DelveInsight’s latest report, “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast 2036” provides a comprehensive analysis of Chronic Kidney Disease (CKD), including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, and commercial opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Request a Sample Report to Gain Deeper Insights into the Chronic Kidney Disease Market Forecast :https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Key Takeaways from the Chronic Kidney Disease Market Report
The Chronic Kidney Disease market size across the 7MM was approximately USD 5 billion in 2025 and is expected to expand significantly through 2036.
In 2025, there were approximately 82.5 million prevalent cases and nearly 14.5 million diagnosed prevalent cases of Chronic Kidney Disease across the 7MM.
The United States represented the largest CKD market, accounting for approximately USD 2.9 billion in 2025.
Germany held the largest market size among EU4 and the UK, reaching nearly USD 480 million in 2025.
Japan accounted for approximately USD 665 million, representing nearly 13% of the total CKD market.
Emerging therapies such as Zibotentan/Dapagliflozin, Vicadrostat (BI 690517) + Empagliflozin, Lorundrostat, and KBP-5074 are expected to reshape the treatment landscape during the forecast period.
Discover Detailed Market Trends and Future Growth Opportunities: https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Chronic Kidney Disease Market Dynamics
The Chronic Kidney Disease market is undergoing significant transformation owing to the increasing prevalence of diabetes, hypertension, obesity, and aging populations worldwide. The growing burden of CKD has accelerated demand for effective therapeutic interventions aimed at slowing disease progression and preventing end-stage renal disease (ESRD).
Advancements in early diagnostic technologies, expanding awareness programs, favorable reimbursement policies, and improvements in healthcare infrastructure are facilitating earlier diagnosis and treatment adoption. Furthermore, increasing investments by pharmaceutical companies in nephrology-focused research and precision medicine approaches are expected to create substantial growth opportunities.
The growing utilization of SGLT2 inhibitors, mineralocorticoid receptor antagonists, and novel combination therapies is reshaping the treatment paradigm while improving clinical outcomes for patients with CKD.
Chronic Kidney Disease Epidemiology Insights
According to DelveInsight’s analysis:
Approximately 82.5 million prevalent cases of CKD were reported across the 7MM in 2025.
Nearly 14.5 million diagnosed prevalent cases were recorded across the 7MM in 2025.
The United States accounted for approximately 3.8 million diagnosed prevalent cases, representing nearly 26% of total diagnosed cases.
Germany reported nearly 2.2 million diagnosed prevalent cases, the highest among EU4 and the UK.
Japan accounted for approximately 2.5 million diagnosed prevalent cases in 2025.
Female patients represented the majority of diagnosed CKD cases in the US, with approximately 2.1 million cases, compared with 1.7 million cases among males.
The diagnosed patient population is expected to increase steadily through 2036 due to demographic shifts and the growing burden of chronic metabolic diseases.
Download the Complete Epidemiology and Forecast Analysis: https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Chronic Kidney Disease Treatment Landscape
Current treatment strategies for CKD focus on slowing disease progression, managing associated complications, and reducing cardiovascular risks.
Common therapeutic classes include:
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARBs)
SGLT2 Inhibitors
Erythropoiesis-Stimulating Agents (ESAs)
Secondary Hyperparathyroidism Treatments
Antidiabetic Therapies
Urate-Lowering Agents
For advanced disease stages, renal replacement therapies such as dialysis and kidney transplantation remain essential treatment options.
Approved therapies including KERENDIA (finerenone) and INVOKANA (canagliflozin) continue to strengthen the current treatment landscape by providing renal and cardiovascular benefits for CKD patients.
Emerging Therapies Driving the Future Chronic Kidney Disease Market
The CKD pipeline remains highly active, with several promising late-stage candidates under evaluation:
Zibotentan/Dapagliflozin (AstraZeneca)
This investigational oral combination therapy combines an endothelin receptor antagonist with an SGLT2 inhibitor, targeting multiple mechanisms involved in CKD progression.
Vicadrostat (BI 690517) + Empagliflozin (Boehringer Ingelheim)
This combination therapy integrates aldosterone synthase inhibition with SGLT2 blockade, offering a novel strategy for reducing kidney damage and preserving renal function.
Lorundrostat (Mineralys Therapeutics)
Lorundrostat is a selective aldosterone synthase inhibitor designed to target hormonal pathways implicated in CKD progression and cardiovascular complications.
KBP-5074 (KBP Biosciences)
KBP-5074 is a Phase III mineralocorticoid receptor antagonist being developed for patients with advanced CKD and uncontrolled hypertension.
Recent Developments in the Chronic Kidney Disease Market
January 2026: Mineralys Therapeutics reported key clinical and regulatory milestones for Lorundrostat in CKD and related indications.
September 2025: eGenesis received FDA clearance for its IND application evaluating EGEN-2784, a genetically engineered porcine kidney, in patients with end-stage kidney disease.
March 2025: FDA expanded approval of Furoscix for treatment of edema in CKD patients, including those with nephrotic syndrome.
January 2025: Novo Nordisk received FDA approval for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD.
November 2024: Unicycive Therapeutics announced FDA acceptance of its NDA for Oxylanthanum Carbonate (OLC) for hyperphosphatemia in dialysis-dependent CKD patients.
Leading Companies in the Chronic Kidney Disease Market
ProKidney
Reata Pharmaceuticals
Novo Nordisk
Boehringer Ingelheim
Eli Lilly and Company
KBP Biosciences
Kibow Pharma
Cincor Pharma
AstraZeneca
Allena Pharmaceuticals
DiaMedica Therapeutics
Lexicon Pharmaceuticals
Sanofi
Mineralys Therapeutics
Chronic Kidney Disease Market Outlook
The future of the Chronic Kidney Disease market appears highly promising as emerging therapies continue to target previously unaddressed mechanisms of disease progression. Growing adoption of precision medicine approaches, increased screening initiatives, and expanding use of kidney-protective therapies are expected to significantly improve patient outcomes.
As multiple pipeline candidates advance toward commercialization and treatment guidelines continue evolving, the CKD market is anticipated to witness robust growth throughout the forecast period.
Learn More About the Chronic Kidney Disease Market Trends, Forecast, and Emerging Therapies: https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Table of Contents (Highlights)
Key Insights
Executive Summary
Disease Background and Overview
Epidemiology and Patient Population Analysis
Current Treatment Practices
Marketed Therapies
Emerging Therapies and Pipeline Analysis
Market Dynamics
Market Forecast (2022–2036)
KOL Perspectives
Reimbursement and Market Access
SWOT Analysis
Conjoint Analysis
Competitive Intelligence
Future Market Opportunities
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve performance and accelerate growth.
The firm’s expertise spans disease market forecasting, competitive intelligence, epidemiology analysis, pipeline assessment, market access, and commercial strategy development.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Mehul MalhotraEmail: Send EmailPhone: 09650213330Address:63, M3M 113 Market, Sector 113 City: GurugramState: IN – IndianaCountry: IndiaWebsite: https://www.delveinsight.com/
